Internal Medicine, Hematology & Oncology · Bayamon, PR
NPI
1164723508
Since 2010
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
135 Villa de la Fuente
Bayamon, PR, 00959
Phone (787) 368-0470
Groups this clinician bills Medicare through
Medicare paid, 2024
$2,481
35 services
Medicare patients, 2024
16
Average age 71
Drug cost, 2024
$5.2M
1,368 prescriptions
Company payments, 2025
$3,623
From 30 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Myrna S Andino-Camacho was code 99213 (office e&m - established), 28 times for 11 patients. In total Myrna S Andino-Camacho billed 35 services in 4 codes, and Medicare paid $2,481.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-09-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 28 | 11 | $61.60 | $1,725 |
By year: 2022 $67K for 4,901 services; 2023 $85K for 2,982 services; 2024 $2,481 for 35 services.
Medicare prescription drug claims, 2024
In 2024, the drug Myrna S Andino-Camacho prescribed most often to Medicare patients was Anastrozole, with 333 prescriptions and refills. In total Myrna S Andino-Camacho wrote 1,368 Medicare prescriptions that cost $5.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 333 | 380 | 56 | $4,647 |
| Dexamethasone Generic | 71 | 71 | 14 | $1,104 |
| Famotidine Generic | 50 | 54 | 17 | $315 |
| Tramadol Hcl Generic | 35 | 35 | 14 | $199 |
| Tagrisso Osimertinib Mesylate | 33 | 33 | Under 11 | $554K |
| Ibrance Palbociclib | 31 | 31 | Under 11 | $498K |
| Exemestane Generic | 31 | 37 | Under 11 | $2,462 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 30 | 30 | Under 11 | $850 |
| Gabapentin Generic | 29 | 29 | Under 11 | $281 |
| Revlimid Lenalidomide | 27 | 27 | Under 11 | $504K |
| Inlyta Axitinib | 27 | 27 | Under 11 | $474K |
| Zejula Niraparib Tosylate | 27 | 27 | Under 11 | $500K |
| Fentanyl Generic | 25 | 25 | Under 11 | $3,831 |
| Kisqali Ribociclib Succinate | 25 | 25 | Under 11 | $441K |
| Letrozole Generic | 24 | 28 | Under 11 | $373 |
Brand drugs: - claims; generic drugs: 948 claims; opioid claims: 90.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Myrna S Andino-Camacho $3,623 ($3,623 in general payments such as food, travel and fees) from 30 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $362.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 16 | $362 |
| Abbvie Inc. ABBV | 14 | $335 |
| Merck Sharp & Dohme LLC MRK | 13 | $312 |
| Pbg Puerto Rico LLC | 13 | $297 |
| E.R. Squibb & Sons, L.L.C. BMY | 11 | $246 |
| Regeneron Healthcare Solutions, Inc. REGN | 8 | $204 |
| Genentech USA, Inc. ROG.SW | 8 | $180 |
| Bayer Puerto Rico Inc. BAYN.DE | 7 | $170 |
| Amgen Inc. AMGN | 8 | $165 |
| Incyte Corporation INCY | 7 | $157 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.